Optimizing Modakafusp Alfa for Relapsed/Refractory Multiple Myeloma | Shebli Atrash, MD | #ASH24

(3:14)

What is MODAKAFUSP ALFA (TAK 573)?

(3:55)

MODAKAFUSP ALFA (TAK-573) | Dan Vogl, MD, MSCE | ASH 2022

(2:57)

Modakafusp alfa combinations for treating multiple myeloma in the near future

(2:38)

Modakafusp alfa for heavily pre-treated myeloma: results of a Phase II dose optimization trial

(4:5)

Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy; Phase 1/2 Study of RRMM Patients

(5:52)

First-in-human study of modakafusp alfa for the treatment of R/R multiple myeloma

(3:9)

Modakafusp alfa: a promising agent in the myeloma treatment landscape

(3:36)

Optimizing the outcomes of autoHSCT in multiple myeloma

(4:)

Optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines

(4:22)

Optimizing multiple myeloma treatment

(1:2)

Optimizing Dosing Regimen in Multiple Myeloma

(21:17)

Optimizing immunotherapy to improve outcomes in myeloma

(4:38)

Dan Fazio - Immune System Optimization

(24:57)

MagnetisMM-3: elranatamab in R/R multiple myeloma naive to BCMA-directed therapy

(6:7)

Optimizing Frontline Therapy in Multiple Myeloma

(3:57)

Optimizing proteasome inhibitors for the treatment of multiple myeloma

(5:15)

Myeloma: Optimizing treatment

(3:31)

Optimizing MM treatment through understanding resistance

(1:7)